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Abstract
1-(3,4,5-Trimethoxyphenyl)ethane-1,2-diyl esters, which share a fragment from (±)-3′-O-4′-O-
bis(3,4-dimethoxycinnamoyl)-cis-khellactone (DMDCK) and 3′R,4′R-disubstituted-2′,2′-
dimethyldihydropyrano[2,3-f]chromone (DSP), exhibited remarkable chemoreversal activity on
multi-drug resistant human nasopharyngeal carcinoma (KB) when combined with three anti-
cancer drugs, paclitaxel, vincristine and doxorubicin. Among 15 novel synthesized analogs, bis-
trimethoxybenzoyl derivative 15 was the most active (340-fold more active than verapamil when
used with vincristine) followed by two di-cinnamoyl derivatives, 10 and 11, and then di-
cyclohexanecarbonyl derivative 9. All aliphatic chain derivatives, 3–5, showed no activity.
Structure-activity relationship study indicated that a di-ester structure was critical to enhance the
activity resulting from the maintenance of the spatial arrangement proposed by the pharmacophore
based on the verapamil-binding site. Further mechanism of action study showed 15 inhibited
mainly P-glycoprotein efflux pump function, while 13 exhibited an additional multidrug
resistance-associated protein efflux pump function.
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Chemotherapy is an important strategy for cancer treatment. However, it is difficult to
eliminate all tumor cells, resulting in relapse with resistant cancer cells. Emerging evidence
suggests that epithelial-mesenchymal transition (EMT)-type cells and cancer stem cells
(CSCs) or initiating cells are more resistant to conventional chemotherapy and are linked to
anticancer drug resistance leading to failure of chemotherapy.1 Another issue of
chemotherapeutic resistance is the tumor microenvironment, in which cancer cells are
surrounded by various sets of non-transformed cells and a heterogenous stromal
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compartment.2 The interaction between tumor cells and normal cells in this tumor
microenvironment occurs via secreted and surface-bound proteins, and is critical for tumor
progression.2
In addition to the tumor microenvironment, cancer cells also adapt other mechanisms to deal
with chemotherapeutic agents.3 Over-expression of drug efflux transporters such as P-
glycoprotein (P-gp) and multidrug resistance-associated proteins (MRPs) is the primary
cause leading to multidrug resistance. Numerous studies have explored chemosensitizer
development. However, clinical drugs are still unavailable.
Verapamil (VRP), the first generation chemosensitizer, was precluded from clinical use due
to its high toxicity, but it is used as a positive control in various chemosensitizing research
efforts. Before the structure of P-glycoprotein (P-gp) was resolved, a pharmacophore model
based on the verapamil-binding site was proposed.4 In this model, the pharmacophore for P-
gp substrates or inhibitors consists of two hydrophobic planes, three optional hydrogen bond
(HB) acceptor points, and one optional HB donor point spatially arranged like a butterfly
shape.4 Based on this model, (±)-3′-O-4′-O-bis-(3,4-dimethoxycinnamoyl)-cis-khellactone
(DMDCK) was found to be a hit and was also confirmed to exhibit chemosensitizing
ability.5 Moreover, 3′R,4′R-disubstituted-2′,2′-dimethyldihydropyrano[2,3-f]chromone
(DSP) analogs sharing similar structures to DMDCK have also been reported to overcome
multidrug resistance (MDR) in an acquired MDR human nasopharyngeal carcinoma (KB)
cell line.6 With inspiration from the above results, a simplified scaffold, 1-(3,4,5-
trimethoxyphenyl)ethane-1,2-diyl ester, was designed (Fig. 1) to provide an ethane-1,2-dilyl
ester partial structure mimicking a fragment in both DSP and DMDCK. By esterifying
different substituents, the importance of the spatial arrangement mentioned in the
pharmacophore model can be evaluated. According to results based on another model, P-gp
inhibitors should show high hydrophobicity, with two or more aromatic rings, a methoxy
group (HB acceptor) on the aromatic ring, and one or two protonatable nitrogens.7
Verapamil also contains two methoxy group on an aromatic ring. In addition, previous study
of DDB substitutions also showed increasing activity along with an increased number of
methoxy substituents.8 Therefore, a trimethoxy-substituted aromatic ring was designed as
the basic scaffold in this study.
1-(3,4,5-Trimethoxyphenyl)ethane-1,2-diol (1), a common intermediate for all synthesized
compounds, was obtained through Wittig reaction of 3,4,5-trimethoxybenzaldehyde
following dihydroxylation with osmium tetroxide and N-methylmorpholine N-oxide
(Scheme 1). Various acyl groups, including linear alkyl (3–5), unsaturated fatty acid (8–9),
cyclic alkyl (6–7), and aromatic (10–15) side chains, were selected for the structure-activity
relationship (SAR) study. Both mono- and di-esters were also synthesized by controlling the
equivalents of the acyl chloride to investigate the importance of the spatial arrangement and
hydrophobicity. Diesterification of diol was achieved with excess acyl chloride under basic
conditions to generate the related diesters, 3, 5–7, 9, and 10. The bulky acyl chlorides, such
as butyryl chloride and cyclohexanecarbonyl chloride, were selectively introduced on only
the primary alcohol to produce mono-ester derivatives, 4 and 8. Monobenzoylester 13 was
prepared through the esterification of the primary alcohol using 1.1 eq. of benzoyl chloride,
following silylation of the secondary alcohol. Halogenated compounds are abundant among
drug candidates. Therefore, iodinated analogs, 2, 11, 12, 14, and 15, were also designed and
synthesized through iodination of 3,4,5-trimethoxybenzaldehyde following the same
reaction sequence as mentioned above (Scheme 1). Newly synthesized derivatives, 1–15
(Table 1), were screened for cytotoxicity and chemoreversal effects on KB and MDR KB
cells in the absence (−) or presence (+) of paclitaxel.
Hung et al. Page 2













Most of the analogs exhibited no significant cytotoxicity at 10 µM against four tumor cell
lines, A549, DU145, KB and KBvin (Supplementary Data, Table S1). Reversal activity of 1-
(3,4,5-trimethoxyphenyl)ethane-1,2-diyl esters using paclitaxel is shown in Table 2. In the
absence of paclitaxel, most compounds had no cytotoxic effect, while chemoreversal effects
were seen on KBvin cells but not on KB cells in the presence of paclitaxel. This result
indicates that these compounds are specifically toxic for MDR KB cells when combined
with the current anticancer drug. Brief SAR correlations were observed as follows. Among
the alkyl esters, acetyl (3), butyryl (4) and dodecanoyl (5) groups showed no chemoreversal
activity. In the case of short fatty acid esters (6 and 7), moderate reversal effects were
observed, indicating a conjugated system may contribute to chemoreversal activity.
Interestingly, compound 9 with bulky di-cyclohexanecarbonyl esters displayed remarkable
reversal activity, while mono-cyclohexanecarbonyl ester (8) totally lost activity. This fact
suggested that di-esters would be better than mono-esters, probably due to higher
hydrophobicity, a critical feature for drug efflux pump inhibitors or the importance of the
butterfly shape proposed in the pharmacophore model.4 The ester derivatives containing an
aromatic ring showed relatively better reversal ability than the aliphatic ester derivatives.
Especially, cinnamoyl ester 10 and 2-iodo-3,4-dimethoxycinnamoyl ester 11, with the same
side chain as DMDCK, totally reversed the cytotoxicity of paclitaxel in the KBvin cell line.
Similarly, 2-iodo-mono-3,4,5-trimethoxybenzoyl (14) as well as –di-3,4,5-
trimethoxybenzoyl (15) esters displayed high chemoreversal effects. These four compounds
resulted in 0% of KBvin cell survival at 10 µM. The comparison of 10 and 11, as well as 12
and 13, suggested that iodination of the C-2 position is not very important for the activity. In
the case of benzoyl ester, similar effects were shown regardless of mono-ester (14) or di-
ester (15). In a comparison of 12 and 14, the silyl group led to reduced chemoreversal when
an iodo group was present at the C-2 position and also increased cytotoxicity in the presence
of paclitaxel. Among the potent derivatives 9–15, compound 12 displayed cytotoxicity.
Therefore, only 9–11 and 13–15, mainly cinnamoyl and trimethoxybenzoyl derivatives,
were selected for further evaluation with three anticancer drugs, paclitaxel, vincristine and
doxorubicin (Table 3). Among the six compounds, trimethoxybenzoyl analogs, 13–15,
generally had better chemoreversal ability than cinnamoyl derivatives (10 and 11) when
combined with the three anticancer drugs. The reversal activity was similar between 10 and
11. Among compounds 13–15 with mono- or di-3,4,5-trimethoxylbenzoyl modification, di-
ester 15 was the most active showing 340-fold more potency than verapamil when used with
vincristine. Compounds 13 with a bulky and hydrophobic tert-butyldimethylsilyl group also
showed significant activity. Cyclohexanoyl ester 9 displayed less activity than the other five
compounds. These results indicated that hydrophobicity, higher electron density on aromatic
group, as well as the maintenance of the spatial arrangement are critical for better
chemoreversal activity.
All of the active compounds (9–11 and 13–15) were further evaluated for effects on P-gp
efflux function in KBvin cells using fluorescent P-gp substrate calcein-AM (Fig. 2).8
Cellular accumulation of calcein was observed in the presence of 10 µM compounds,
demonstrating that the compounds prevent calcein-AM efflux from KBvin cells by
inhibiting P-gp. Compound 15 exhibited two-fold more calcein accumulation than verapamil
at the same concentration, indicating 15 is more potent than verapamil at inhibiting P-gp
function. Although 13 showed strong reversal activity compared with verapamil, its
inhibitory effect on the P-gp efflux pump was relatively weaker than verapamil. Hence, 13
may inhibit other drug transporters, such as multidrug resistance-associated proteins
(MRPs). The inhibitory effect of 13 on MRPs can be determined by using a fluorogenic
MRP substrate Fluo-3 AM, which is accumulated in KB cells and pumped out from KBvin
cells (Fig. 3). Although no significant Fluo-3 fluororescence was seen in KBvin cells pre-
treated with 15, cellular accumulation of Fluo-3 was observed in KBvin cells pre-treated
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with 13. These results demonstrate that 13 inhibits efflux pump function of MRPs, whereas
15 does not affect MRPs. Taken together, 15 selectively inhibits P-gp and 13 can interfere
with both P-gp and MRPs.
In this study, we demonstrated that a simplified scaffold containing the core of DMDCK and
DSP exhibited excellent chemoreversal activity. Fifteen ester analogs were designed,
synthesized, and evaluated for chemoreversal activity. Based on the results, di-ester
modification is critical for better activity, indicating the importance of maintaining the
spatial arrangement of the compound. SAR study indicates that di-trimethoxylbenzoyl
substitution resulted in the most activity, followed by di-3,4-dimethoxylcinnamoyl and then
di-cycloheanecarbonyl substitutions. Aliphatic groups, such as acetyl or butyryl, led to no
activity. Mechanism of action study showed that these compounds inhibited the drug efflux
function of P-gp, which increases the cellular accumulation of anticancer drugs, such as
paclitaxel, vincristine, and doxorubicin. Moreover, compound 13 showed additional
inhibitory activity against MRPs. Further modifications and more detailed SAR will be
reported in the near future.
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Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This study was supported by grant CA-17625-32 from the National Cancer Institute, NIH, awarded to K. H. Lee.
Support in part was also due to the Cancer Research Center of Excellence (CRC) (DOH-100-TD-C-111-005). We
would like to thank Dr. Mitch Eddy (NIEHS/NIH) for providing a fluorescence microscope.
References
1. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the
war on cancer. Oncogene. 2010; 29:4741. [PubMed: 20531305]
2. Gilbert LA, Hemann MT. Chemotherapeutic resistance: surviving stressful situations. Cancer Res.
2011; 71:5062. [PubMed: 21771909]
3. Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do
cancer cells develop chemoresistance? Cancer J. 2011; 17:89. [PubMed: 21427552]
4. Pajeva IK, Wiese M. Pharmacophore model of drugs involved in P-glycoprotein multidrug
resistance: explanation of structural variety (hypothesis). J. Med. Chem. 2002; 45:5671. [PubMed:
12477351]
5. Fong WF, Shen XL, Globisch C, Wiese M, Chen GY, Zhu GY, Yu ZL, Tse AK, Hu YJ.
Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug
resistance reversal activities of 7,8-pyranocoumarin against cancer cells. Bioorg. Med. Chem. 2008;
16:3694. [PubMed: 18313307]
6. Zhou T, Shi Q, Bastow KF, Lee KH. Antitumor agents 286. Design, synthesis, and structure-activity
relationships of 3'R,4'R-disubstituted-2',2'-dimethyldihydropyrano[2,3-f]chromone (DSP) analogues
as potent chemosensitizers to overcome multidrug resistance. J. Med. Chem. 2010; 53:8700.
[PubMed: 21082774]
7. Pajeva IK, Globisch C, Wiese M. Combined pharmacophore modeling, docking, and 3D QSAR
studies of ABCB1 and ABCC1 transporter inhibitors. Chem Med Chem. 2009; 4:1883. [PubMed:
19768722]
8. Hung HY, Ohkoshi E, Goto M, Bastow KF, Nakagawa-Goto K, Lee KH. Antitumor Agents 293.
Non-toxic dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate
(DDB) analogs chemosensitize multidrug resistant cancer cells to clinical anticancer drugs. J. Med.
Chem. 2012; 14:5413. [PubMed: 22612652]
Hung et al. Page 4













Figure 1. Structures of (±) DMDCK, DSP, and Verapamil and Proposed Structure for This
Study
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Figure 2. Inhibitory Effects of Compounds on P-gp Function in KBvin Cells
The KBvin cells were pretreated with the compounds (10 µM) followed by addition of
calcein-AM. The cellular accumulation of calcein is represented by fluorescent units (FLU).
Cellular accumulation of calcein demonstrates inhibition of efflux activity of Pgp. Data with
mean ± SD of three independent experiments are shown in suppl. Table S2.
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Figure 3. Effect of 13 on MRP Function in KBvin Cells
KB (a) or KBvin (b, c, d) cells were pre-treated with DMSO (a, b), 13 (c), or 15 (d) for 1 h
before addition of Fluo-3 AM for 2 h. Cellular accumulation of Fluo-3, a fluorescence
MRPs substrate, was observed in KB cells (a), and effluxed from KBvin cells (b). Cellular
retention of Fluo-3 fluorescence was observed in KBvin cells treated with 13 (c) yet
undetectable in cells treated with 15 (d). (Bar, 50 µm.)
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Scheme 1. Synthetic Route to 1-(3,4,5-Trimethoxyphenyl)ethane-1,2-diyl Esters
Hung et al. Page 8

























Hung et al. Page 9
Table 1
Structures of 1-(3,4,5-Trimethoxyphenyl)ethane-1,2-diyl Esters.
No. X R R′
1 H H H
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No. X R R′
14 I H
15 I
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